Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5
Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis. Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or contr...
Gespeichert in:
Veröffentlicht in: | Critical care medicine 2013-02, Vol.41 (2), p.546-553 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 553 |
---|---|
container_issue | 2 |
container_start_page | 546 |
container_title | Critical care medicine |
container_volume | 41 |
creator | SU, George ATAKILITL, Amha LI, John T NANYAN WU LUONG, Jacky CHEN, Robert BHATTACHARYA, Mallar SHEPPARD, Dean |
description | Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis.
Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or control antibodies were tested in models of intraperitoneal lipopolysaccharide and cecal ligation and puncture. Human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers were treated with αvβ5 antibodies to assess for effects on lipopolysaccharide-induced changes in transendothelial resistance and on patterns of cytoskeletal reorganization.
Laboratory-based research.
Mice and endothelial cell monolayers.
Measurements taken after intraperitoneal lipopolysaccharide and/or cecal ligation and puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines/chemokines, and assessment of thioglyccolate-induced leukocyte migration. β5 knockout mice had decreased mortality after intraperitoneal lipopolysaccharide and cecal ligation and puncture and decreased vascular leak, as measured by extravasation of an I-labeled intravascular tracer. Treating clinically ill mice with αvβ5 antibodies, up to 20 hrs after intraperitoneal lipopolysaccharide and cecal ligation and puncture, also resulted in decreased mortality. αvβ5 antibodies attenuated lipopolysaccharide-induced transendothelial resistance changes and cytoskeletal stress fiber formation in both human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers. αvβ5 antibodies had no effect on cytokine/chemokine serum levels after cecal ligation and puncture. β5 knockout mice and wild-type controls did not exhibit differences in thioglyccolate-induced leukocyte migration.
Our studies suggest that αvβ5 is an important regulator of the vascular endothelial leak response in sepsis and that αvβ5 blockade may provide a novel approach to treating this devastating disease syndrome. |
doi_str_mv | 10.1097/CCM.0b013e3182711b1e |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1282514168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1282514168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-169ecb4eb28c201727b4050c1c0615364bd218a3126d39194cd0b77a5c7116ab3</originalsourceid><addsrcrecordid>eNpdkM9O4zAQh63VoqXAvgFCvqzEJTBjx05yRBX_JBAHitCeItuZFKM26douUh8LHqTPRFALK3Gaw3y_Gf0-xg4RThCq4nQ8vj0BCyhJYikKRIv0g41QSchAVPInGwFUkMm8krtsL8ZnAMxVIX-xXSGFlqrAEft73rbkkn8hPglk0py6xPuW3_bLSPyeFtFH_ujTEzcdv-6evPWpDyt-1iVv-2bFJyZMKfluOmwTTYPv-Pr1Zf2mDthOa2aRfm_nPnu4OJ-Mr7Kbu8vr8dlN5oQSKUNdkbM5WVE6AViIwuagwKEDPXTRuW0Elkai0I2ssMpdA7YojHJDZW2s3GfHm7uL0P9bUkz13EdHs5npaChRoyiFwhx1OaD5BnWhjzFQWy-Cn5uwqhHqD6n1ILX-LnWIHW0_LO2cmq_Qp8UB-LMFTHRm1gbTOR__c7oCraSU76D0gKI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1282514168</pqid></control><display><type>article</type><title>Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>SU, George ; ATAKILITL, Amha ; LI, John T ; NANYAN WU ; LUONG, Jacky ; CHEN, Robert ; BHATTACHARYA, Mallar ; SHEPPARD, Dean</creator><creatorcontrib>SU, George ; ATAKILITL, Amha ; LI, John T ; NANYAN WU ; LUONG, Jacky ; CHEN, Robert ; BHATTACHARYA, Mallar ; SHEPPARD, Dean</creatorcontrib><description>Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis.
Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or control antibodies were tested in models of intraperitoneal lipopolysaccharide and cecal ligation and puncture. Human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers were treated with αvβ5 antibodies to assess for effects on lipopolysaccharide-induced changes in transendothelial resistance and on patterns of cytoskeletal reorganization.
Laboratory-based research.
Mice and endothelial cell monolayers.
Measurements taken after intraperitoneal lipopolysaccharide and/or cecal ligation and puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines/chemokines, and assessment of thioglyccolate-induced leukocyte migration. β5 knockout mice had decreased mortality after intraperitoneal lipopolysaccharide and cecal ligation and puncture and decreased vascular leak, as measured by extravasation of an I-labeled intravascular tracer. Treating clinically ill mice with αvβ5 antibodies, up to 20 hrs after intraperitoneal lipopolysaccharide and cecal ligation and puncture, also resulted in decreased mortality. αvβ5 antibodies attenuated lipopolysaccharide-induced transendothelial resistance changes and cytoskeletal stress fiber formation in both human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers. αvβ5 antibodies had no effect on cytokine/chemokine serum levels after cecal ligation and puncture. β5 knockout mice and wild-type controls did not exhibit differences in thioglyccolate-induced leukocyte migration.
Our studies suggest that αvβ5 is an important regulator of the vascular endothelial leak response in sepsis and that αvβ5 blockade may provide a novel approach to treating this devastating disease syndrome.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/CCM.0b013e3182711b1e</identifier><identifier>PMID: 23263571</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Antibodies - pharmacology ; Biological and medical sciences ; Cecum - surgery ; Cell Movement ; Chemokines - blood ; Cytokines - blood ; Disease Models, Animal ; Emergency and intensive care: infection, septic shock ; Endothelial Cells - drug effects ; Humans ; Injections, Intraperitoneal ; Intensive care medicine ; Leukocytes - physiology ; Ligation ; Lipopolysaccharides - administration & dosage ; Medical sciences ; Mice ; Mice, 129 Strain ; Mice, Knockout ; Punctures ; Receptors, Vitronectin - antagonists & inhibitors ; Receptors, Vitronectin - genetics ; Sepsis - therapy</subject><ispartof>Critical care medicine, 2013-02, Vol.41 (2), p.546-553</ispartof><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c252t-169ecb4eb28c201727b4050c1c0615364bd218a3126d39194cd0b77a5c7116ab3</citedby><cites>FETCH-LOGICAL-c252t-169ecb4eb28c201727b4050c1c0615364bd218a3126d39194cd0b77a5c7116ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26906533$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23263571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SU, George</creatorcontrib><creatorcontrib>ATAKILITL, Amha</creatorcontrib><creatorcontrib>LI, John T</creatorcontrib><creatorcontrib>NANYAN WU</creatorcontrib><creatorcontrib>LUONG, Jacky</creatorcontrib><creatorcontrib>CHEN, Robert</creatorcontrib><creatorcontrib>BHATTACHARYA, Mallar</creatorcontrib><creatorcontrib>SHEPPARD, Dean</creatorcontrib><title>Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis.
Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or control antibodies were tested in models of intraperitoneal lipopolysaccharide and cecal ligation and puncture. Human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers were treated with αvβ5 antibodies to assess for effects on lipopolysaccharide-induced changes in transendothelial resistance and on patterns of cytoskeletal reorganization.
Laboratory-based research.
Mice and endothelial cell monolayers.
Measurements taken after intraperitoneal lipopolysaccharide and/or cecal ligation and puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines/chemokines, and assessment of thioglyccolate-induced leukocyte migration. β5 knockout mice had decreased mortality after intraperitoneal lipopolysaccharide and cecal ligation and puncture and decreased vascular leak, as measured by extravasation of an I-labeled intravascular tracer. Treating clinically ill mice with αvβ5 antibodies, up to 20 hrs after intraperitoneal lipopolysaccharide and cecal ligation and puncture, also resulted in decreased mortality. αvβ5 antibodies attenuated lipopolysaccharide-induced transendothelial resistance changes and cytoskeletal stress fiber formation in both human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers. αvβ5 antibodies had no effect on cytokine/chemokine serum levels after cecal ligation and puncture. β5 knockout mice and wild-type controls did not exhibit differences in thioglyccolate-induced leukocyte migration.
Our studies suggest that αvβ5 is an important regulator of the vascular endothelial leak response in sepsis and that αvβ5 blockade may provide a novel approach to treating this devastating disease syndrome.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Antibodies - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cecum - surgery</subject><subject>Cell Movement</subject><subject>Chemokines - blood</subject><subject>Cytokines - blood</subject><subject>Disease Models, Animal</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Endothelial Cells - drug effects</subject><subject>Humans</subject><subject>Injections, Intraperitoneal</subject><subject>Intensive care medicine</subject><subject>Leukocytes - physiology</subject><subject>Ligation</subject><subject>Lipopolysaccharides - administration & dosage</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, 129 Strain</subject><subject>Mice, Knockout</subject><subject>Punctures</subject><subject>Receptors, Vitronectin - antagonists & inhibitors</subject><subject>Receptors, Vitronectin - genetics</subject><subject>Sepsis - therapy</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkM9O4zAQh63VoqXAvgFCvqzEJTBjx05yRBX_JBAHitCeItuZFKM26douUh8LHqTPRFALK3Gaw3y_Gf0-xg4RThCq4nQ8vj0BCyhJYikKRIv0g41QSchAVPInGwFUkMm8krtsL8ZnAMxVIX-xXSGFlqrAEft73rbkkn8hPglk0py6xPuW3_bLSPyeFtFH_ujTEzcdv-6evPWpDyt-1iVv-2bFJyZMKfluOmwTTYPv-Pr1Zf2mDthOa2aRfm_nPnu4OJ-Mr7Kbu8vr8dlN5oQSKUNdkbM5WVE6AViIwuagwKEDPXTRuW0Elkai0I2ssMpdA7YojHJDZW2s3GfHm7uL0P9bUkz13EdHs5npaChRoyiFwhx1OaD5BnWhjzFQWy-Cn5uwqhHqD6n1ILX-LnWIHW0_LO2cmq_Qp8UB-LMFTHRm1gbTOR__c7oCraSU76D0gKI</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>SU, George</creator><creator>ATAKILITL, Amha</creator><creator>LI, John T</creator><creator>NANYAN WU</creator><creator>LUONG, Jacky</creator><creator>CHEN, Robert</creator><creator>BHATTACHARYA, Mallar</creator><creator>SHEPPARD, Dean</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5</title><author>SU, George ; ATAKILITL, Amha ; LI, John T ; NANYAN WU ; LUONG, Jacky ; CHEN, Robert ; BHATTACHARYA, Mallar ; SHEPPARD, Dean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-169ecb4eb28c201727b4050c1c0615364bd218a3126d39194cd0b77a5c7116ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Antibodies - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cecum - surgery</topic><topic>Cell Movement</topic><topic>Chemokines - blood</topic><topic>Cytokines - blood</topic><topic>Disease Models, Animal</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Endothelial Cells - drug effects</topic><topic>Humans</topic><topic>Injections, Intraperitoneal</topic><topic>Intensive care medicine</topic><topic>Leukocytes - physiology</topic><topic>Ligation</topic><topic>Lipopolysaccharides - administration & dosage</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, 129 Strain</topic><topic>Mice, Knockout</topic><topic>Punctures</topic><topic>Receptors, Vitronectin - antagonists & inhibitors</topic><topic>Receptors, Vitronectin - genetics</topic><topic>Sepsis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SU, George</creatorcontrib><creatorcontrib>ATAKILITL, Amha</creatorcontrib><creatorcontrib>LI, John T</creatorcontrib><creatorcontrib>NANYAN WU</creatorcontrib><creatorcontrib>LUONG, Jacky</creatorcontrib><creatorcontrib>CHEN, Robert</creatorcontrib><creatorcontrib>BHATTACHARYA, Mallar</creatorcontrib><creatorcontrib>SHEPPARD, Dean</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SU, George</au><au>ATAKILITL, Amha</au><au>LI, John T</au><au>NANYAN WU</au><au>LUONG, Jacky</au><au>CHEN, Robert</au><au>BHATTACHARYA, Mallar</au><au>SHEPPARD, Dean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2013-02</date><risdate>2013</risdate><volume>41</volume><issue>2</issue><spage>546</spage><epage>553</epage><pages>546-553</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>Integrin αvβ5 has been identified as a regulator of vascular leak and endothelial permeability. We hypothesized that targeting αvβ5 could represent a viable treatment strategy for sepsis.
Integrin β5 subunit knockout and wild-type 129/svJae mice and wild-type mice treated with αvβ5 blocking or control antibodies were tested in models of intraperitoneal lipopolysaccharide and cecal ligation and puncture. Human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers were treated with αvβ5 antibodies to assess for effects on lipopolysaccharide-induced changes in transendothelial resistance and on patterns of cytoskeletal reorganization.
Laboratory-based research.
Mice and endothelial cell monolayers.
Measurements taken after intraperitoneal lipopolysaccharide and/or cecal ligation and puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines/chemokines, and assessment of thioglyccolate-induced leukocyte migration. β5 knockout mice had decreased mortality after intraperitoneal lipopolysaccharide and cecal ligation and puncture and decreased vascular leak, as measured by extravasation of an I-labeled intravascular tracer. Treating clinically ill mice with αvβ5 antibodies, up to 20 hrs after intraperitoneal lipopolysaccharide and cecal ligation and puncture, also resulted in decreased mortality. αvβ5 antibodies attenuated lipopolysaccharide-induced transendothelial resistance changes and cytoskeletal stress fiber formation in both human umbilical vein endothelial cell and human lung microvascular endothelial cell monolayers. αvβ5 antibodies had no effect on cytokine/chemokine serum levels after cecal ligation and puncture. β5 knockout mice and wild-type controls did not exhibit differences in thioglyccolate-induced leukocyte migration.
Our studies suggest that αvβ5 is an important regulator of the vascular endothelial leak response in sepsis and that αvβ5 blockade may provide a novel approach to treating this devastating disease syndrome.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>23263571</pmid><doi>10.1097/CCM.0b013e3182711b1e</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-3493 |
ispartof | Critical care medicine, 2013-02, Vol.41 (2), p.546-553 |
issn | 0090-3493 1530-0293 |
language | eng |
recordid | cdi_proquest_miscellaneous_1282514168 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Antibodies - pharmacology Biological and medical sciences Cecum - surgery Cell Movement Chemokines - blood Cytokines - blood Disease Models, Animal Emergency and intensive care: infection, septic shock Endothelial Cells - drug effects Humans Injections, Intraperitoneal Intensive care medicine Leukocytes - physiology Ligation Lipopolysaccharides - administration & dosage Medical sciences Mice Mice, 129 Strain Mice, Knockout Punctures Receptors, Vitronectin - antagonists & inhibitors Receptors, Vitronectin - genetics Sepsis - therapy |
title | Effective Treatment of Mouse Sepsis With an Inhibitory Antibody Targeting Integrin αvβ5 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T21%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20Treatment%20of%20Mouse%20Sepsis%20With%20an%20Inhibitory%20Antibody%20Targeting%20Integrin%20%CE%B1v%CE%B25&rft.jtitle=Critical%20care%20medicine&rft.au=SU,%20George&rft.date=2013-02&rft.volume=41&rft.issue=2&rft.spage=546&rft.epage=553&rft.pages=546-553&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/CCM.0b013e3182711b1e&rft_dat=%3Cproquest_cross%3E1282514168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1282514168&rft_id=info:pmid/23263571&rfr_iscdi=true |